systematic sampling, but is avoided in trials with patients prospectively randomised and analysed on an intention-to-treat basis. We emphasise that we did not perform any stage-based subanalyses, but compared the whole CMLND population with the systematic sampling group.

The exclusions after randomisation clearly should not have occurred, but were adequately reported. In all, 25 patients had small-cell cancer or a non-malignant pathology, 48 had incomplete primary resection, 5 turned out to have metastatic deposits from other sites and 15 were excluded because of upstaging to IIIB or IV only. The exclusions were well matched, with 52 occurring in the CMLND group and 41 in the systematic sampling group. We therefore believe this had little effect on the overall analysis.

It should also be mentioned that in one of the trials, only patients with cT1N0 adenocarcinoma of ≤ 2 cm diameter were randomised. Mechanistically, the authors hypothesised that this is the group least likely to benefit from CMLND; however, their inclusion in the pooled analysis still resulted in a clear benefit in favour of CMLND. In fact, the pooled hazard ratio of 0.78 is superior to that of adjuvant chemotherapy meta-analyses⁴ that have created such enthusiasm in lung cancer circles of late. Therefore, we are concerned that as a result of this editorial, groups treating lung cancer may not demand from their surgeons that which they are demanding from their medical oncologists—an evidence-based improvement in survival with an adjuvant intervention.

We also await the results of the ACOSOG Z30 trial,⁵ which will address this question for patients in clinical stage I. This will also allow a pooled analysis of 1959 patients, which should be able to put this question to rest after 50 years of controversy. Until then, the level I evidence is that CMLND should be performed as part of the surgical treatment of patients with stage I–IIIA non-small-cell lung cancer.

Gavin M Wright

Correspondence to: G M Wright, St Vincent's Hospital, 55 Victoria Parade Fitzroy, Melbourne 3065, Victoria, Australia; gavin.wright@svhm.org.au

Competing interests: None declared.

References

- 1 Wright G, Manser RL, Byrnes G, *et al*. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. *Thorax* 2006;**61**:597–603.

- 2 Holty J-EC, Gould MK. When in doubt should we cut it out? The role of surgery in non-small cell lung cancer. *Thorax* 2006;**61**:554–6.
- 3 Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. *N Engl J Med* 1985;**312**:1604–8.
- 4 Pignon JP, Tirbode H, Scagliotti GV, *et al*. Lung Adjuvant Cisplatin Evaluation: a pooled analysis of five randomised clinical trials including 4,584 patients. *Proc Am Soc Clin Oncol* 2006;**24**(Part 1):No 188, 7008.
- 5 Allen MS, Darling GE, Pechet TT, *et al*. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. *Ann Thorac Surg* 2006;**81**:1013–19.

Authors' reply

We thank Dr Wright for his comments, but respectfully disagree. Although it is certainly possible that complete mediastinal lymph node dissection (CMLD) might improve survival in non-small-cell lung cancer (NSCLC), all three of the studies performed to date were limited by stage migration and other biases. Although overall exclusions were matched, we do not know whether exclusions due to upstaging were necessarily matched between study arms. In fact, limited data from the studies suggest that they were not. In the study by Wu *et al*,¹ after post-randomisation exclusions, there were more patients with stage I (42% *v* 24%) and fewer with stage IIIa (28% *v* 48%) in the lymph node sampling group than in the CMLD group. Furthermore, the authors of one of the other three included studies concluded that stage migration might have resulted in an observed survival benefit for patients undergoing CMLD,² and a previous systematic review on CMLD in NSCLC also concluded that stage migration existed for two of the three included studies.³

In addition, there are other limitations. For example, because the study by Sugi *et al*⁴ included only patients with peripheral NSCLC < 2 cm, the results are not generalisable to all patients with early-stage disease. The study by Wu *et al* had unequal follow-up between study arms.^{1,3} The study by Izbicki *et al*² had significantly more patients with squamous cell carcinoma in the lymph node sampling group (53%) than in the CMLD group (32%, $p = 0.03$). Finally, two of the three studies were unblinded during follow-up.^{1,4} Even if a small survival benefit exists, this must be weighed against the substantially higher morbidity for patients undergoing CMLD reported in two of the three included studies.^{2,4} The results of the ACOSOG Z30 trial should help address these trade-offs.⁵

J-E C Holty

Center for Primary Care and Outcomes Research, Stanford, University, Stanford, California, USA

M K Gould

VA Palo Alto Health Care System, Palo Alto, California, USA; Stanford University Medical Center, Palo Alto, California, USA; Center for Primary Care and Outcomes Research, Stanford University, Stanford, California, USA

Correspondence to: Dr J-E C Holty, Division of Pulmonary and Critical Care Medicine, University School of Medicine, 300 Pasteur Drive, H3143, Stanford, CA 94305-5236, USA; jholty@stanford.edu

Competing interests: None declared.

References

- 1 Wu YL, Huang ZF, Wang SY, *et al*. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. *Lung Cancer* 2002;**36**:1–6.
- 2 Izbicki J, Passlick B, Pantel K, *et al*. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. *Ann Surg* 1998;**227**:138–44.
- 3 Barnard J, Dunning J, Musleh G, *et al*. Is there a role for the use of radical lymph node dissection in the surgical management of resectable non-small cell lung cancer? *Interact Cardiovasc Thorac Surg* 2004;**3**:294–9.
- 4 Sugi K, Nawata K, Fujita N, *et al*. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. *World J Surg* 1998;**22**:290–5.
- 5 Allen MS, Darling GE, Pechet TTV, *et al*. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. *Ann Thorac Surg* 2006;**81**:1013–20.

CORRECTION

doi: 10.1136/thx.2006.063271corr1

The authors of the article entitled "Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis" (Barr RG, Bourbeau J, Camargo CA, *et al*. *Thorax* 2006;**61**:854–62), published in the October issue, have noticed an error in figure 1. Reference 26 in figure 1 should refer to a paper not in the reference list: Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. *Eur Respir J* 2003;**21**:267–72. Where reference 26 is cited in the text this correctly refers to the paper listed in the reference list.